Abrir sesión | Regístrese | ¿Olvidó su contraseña? | Contacto | English |
Email: Clave:

Medwave se preocupa por su privacidad y la seguridad de sus datos personales.
Para poder enviarle a su dirección de correo electrónico su contraseña, es necesario que ingrese su e-mail.


Comentarios
Medwave 2017 Sep-Oct;17(8):7079 doi: 10.5867/medwave.2017.08.7079
Vacunación contra el virus del papiloma humano para niños en Brasil
Human papillomavirus vaccination for boys in Brazil
Marcos Roberto Tovani-Palone
Referencias | Descargar PDF |
Para Descargar PDF debe Abrir sesión.
Imprimir | A(+) A(-) | Lectura fácil

Last year, the Brazilian Ministry of Health announced the decision to start as of 2017 the quadrivalent vaccination against human papillomavirus for boys aged 12 to 13 years [1]. Such vaccine protects against infection by human papillomavirus subtypes 6, 11, 16 and 18 (in the same way as for girls) [2],[3].

Brazil is, therefore, the first country in South America that has protected boys against human papillomavirus infection through mass vaccination as part of the national immunization program [1],[4]. In this context, it should be noted that the human papillomavirus vaccination can result in a considerable reduction of new cases of cancer of the penis, anus and oropharynx [2],[4].

However, no data about the human papillomavirus vaccination campaigns for boys in Brazil, their consequences, as well as the corresponding impacts for the public health system have been published in the scientific literature. This article, then, discusses the more recent information about this subject matter.

In March 2017, surprisingly, the government has signed a partnership between the Ministries of Health and Education. Its objective has been to increase immunization coverage of children and adolescents against human papillomavirus. Thus, one of the proposals for the human papillomavirus vaccination in schools requires, for example, that students present their vaccination booklet at the time of school enrollment. Once this is done, the health system must be communicated about the priority doses [2],[5].

This action has been a very important advance, since for achieving a successful outcome in the human papillomavirus vaccination, the implementation of integrated public policies is required.

Nevertheless, according to the Brazilian Minister of Health more than two thousand vaccine doses have already surpassed expiration date. Moreover, there is a stock of 231,000 human papillomavirus vaccines with expiration dates in the month of August [2],[6].

This large surplus of human papillomavirus vaccine is, in turn, due to the low adhesion rate to the vaccination campaign by the target public [2],[6]. Anti-vaccination movements (that disseminate information against the practice of vaccination) and fear of the vaccine might be the main reasons for this low current demand [3],[7].

In view of that, in June 2017 the Brazilian Ministry of Health has extended the age range of boys for human papillomavirus vaccination, by reducing the lower age limit to 11 and increasing the upper limit to 15 years incomplete. Such expansion of the age range is aimed at using human papillomavirus vaccines before the expiration date, while at the same time a greater number of boys are protected against this infection. Thereby, around seven million boys can be immunized through human papillomavirus vaccination campaign, which can also contribute to greater protection for girls [2],[6].

Therefore, it seems prudent for the Ministry of Health to implement new integrated public policies aimed at improvements in this issue. Health education in schools and adequate training of health professionals to assist the target public should be priority [1]. Nevertheless, completing these tasks can be very difficult, since there are serious weaknesses in the public management of a great number of Brazilian municipalities [8],[9].

In conclusion, although human papillomavirus vaccination is a very important preventive measure, it does not protect against all subtypes of this virus [3] and it has had low demand by the Brazilian population [2],[6]. In this sense, a complementary option would be the establishment of adjustments in the Brazilian public health system for the provision of effective cancer screening programs (resulting from human papillomavirus infection) for pre-adolescents and adolescents [3]. At least for the moment, to promote this additional action would be a great help.

Notes

From the editor
The authors originally submitted this article in Spanish and subsequently translated it into English. The Journal has not copyedited this version.

Declaration of conflicts of interest
The author has completed the ICMJE's conflict of interest declaration form translated into Spanish by Medwave, and declares he has not received funding for the report; has no financial relationships with organizations that might have an interest in the published article in the last three years; and has no other relationships or activities that could influence the published article. Forms can be requested by contacting the author responsible or the editorial management of the Journal.

Financing
The author states that there were no external sources of funding.

Licencia Creative Commons Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

 

Autor: Marcos Roberto Tovani-Palone[1]

Filiación:
[1] Facultad de Medicina de Ribeirão Preto, Universidad de São Paulo, Ribeirão Preto, Brasil

E-mail: marcos_palone@hotmail.com

Correspondencia a:
[1] Avenida Bandeirantes 3900
Ribeirão Preto
Brasil

Citación: Tovani-Palone MR. Human papillomavirus vaccination for boys in Brazil. Medwave 2017 Sep-Oct;17(8):7079 doi: 10.5867/medwave.2017.08.7079

Fecha de envío: 24/7/2017

Fecha de aceptación: 10/10/2017

Fecha de publicación: 30/10/2017

Origen: no solicitado

Tipo de revisión: con revisión por cuatro pares revisores externos, a doble ciego

Ficha PubMed

Comentarios (0)

Nos complace que usted tenga interés en comentar uno de nuestros artículos. Su comentario será publicado inmediatamente. No obstante, Medwave se reserva el derecho a eliminarlo posteriormente si la dirección editorial considera que su comentario es: ofensivo en algún sentido, irrelevante, trivial, contiene errores de lenguaje, contiene arengas políticas, obedece a fines comerciales, contiene datos de alguna persona en particular, o sugiere cambios en el manejo de pacientes que no hayan sido publicados previamente en alguna revista con revisión por pares.

Aún no hay comentarios en este artículo.


Para comentar debe iniciar sesión

Medwave publica las vistas HTML y descargas PDF por artículo, junto con otras métricas de redes sociales.

Se puede producir un retraso de 48 horas en la actualización de las estadísticas.

  1. Tovani-Palone MR, Sanches TT. Vaccination against HPV in Brazil: what is new in the year 2017? Rev Fac Med 2017. En imprenta.
  2. Ministerio de Salud de Brasil. Portal da saúde - Vacina de HPV é ampliada para meninos de 11 a 15 anos incompletos. [online]. | Link |
  3. Sanches TT, Siqueira-Oliveira T, Papp-Moretti C, Tovani-Palone MR, Hishinuma G. Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes. Rev Fac Med.2017;65(1):115-20. | CrossRef |
  4. Ministerio de Salud de Brasil. Portal Brasil - Cobertura da vacinação contra HPV pelo SUS é ampliada. [online]. | Link |
  5. Ministerio de Salud de Brasil. Portal Brasil - Cooperação ampliará vacinação de crianças e adolescentes [online]. | Link |
  6. Cristaldo H. Ministério da Saúde anuncia vacinação contra HPV para meninos de 11 a 15 anos. Agência Brasil, June 20, 2017 [online]. | Link |
  7. Roitman B. HPV: uma nova vacina na rede pública. Bol Cient Pediatr. 2015;4(1):3-4. | Link |
  8. Araújo CEL, Gonçalves GQ, Machado JA. Os municípios brasileiros e os gastos próprios com saúde: algumas associações. Ciênc Saúde Coletiva. 2017 Mar;22(3):953-63. | CrossRef | PubMed |
  9. Lourenço RL, Angotti M, Nascimento JCHB, Sauerbronn FF. Eficiência do gasto público com ensino fundamental: uma análise dos 250 maiores municípios brasileiros. Contabilidade Vista & Revista. 2017; 28(1):89-116. | Link |
Tovani-Palone MR, Sanches TT. Vaccination against HPV in Brazil: what is new in the year 2017? Rev Fac Med 2017. En imprenta.

Ministerio de Salud de Brasil. Portal da saúde - Vacina de HPV é ampliada para meninos de 11 a 15 anos incompletos. [online]. | Link |

Sanches TT, Siqueira-Oliveira T, Papp-Moretti C, Tovani-Palone MR, Hishinuma G. Evolução do sistema público de saúde no Brasil frente ao estágio atual da prevenção do câncer de colo uterino em mulheres jovens e adolescentes. Rev Fac Med.2017;65(1):115-20. | CrossRef |

Ministerio de Salud de Brasil. Portal Brasil - Cobertura da vacinação contra HPV pelo SUS é ampliada. [online]. | Link |

Ministerio de Salud de Brasil. Portal Brasil - Cooperação ampliará vacinação de crianças e adolescentes [online]. | Link |

Cristaldo H. Ministério da Saúde anuncia vacinação contra HPV para meninos de 11 a 15 anos. Agência Brasil, June 20, 2017 [online]. | Link |

Roitman B. HPV: uma nova vacina na rede pública. Bol Cient Pediatr. 2015;4(1):3-4. | Link |

Araújo CEL, Gonçalves GQ, Machado JA. Os municípios brasileiros e os gastos próprios com saúde: algumas associações. Ciênc Saúde Coletiva. 2017 Mar;22(3):953-63. | CrossRef | PubMed |

Lourenço RL, Angotti M, Nascimento JCHB, Sauerbronn FF. Eficiência do gasto público com ensino fundamental: uma análise dos 250 maiores municípios brasileiros. Contabilidade Vista & Revista. 2017; 28(1):89-116. | Link |